Literature DB >> 6842807

Thioridazine-induced torsade de pointes. Successful therapy with isoproterenol.

A J Kemper, R Dunlap, D A Pietro.   

Abstract

Thioridazine (Mellaril) hydrochloride cardiotoxicity is manifested by bradycardia and prolongation of the QT interval. The latter predisposes to atypical ventricular tachycardia (torsade de pointes) when premature ventricular depolarizations occur during the prolonged QT interval. Isoproterenol hydrochloride infusion, which increases the heart rate and shortens the QT interval, is a theoretically advantageous therapeutic modality for use in this situation. This report describes a case of thioridazine-induced torsade de pointes that was successfully managed with isoproterenol infusion after therapy with other agents was unsuccessful. This mode of therapy should be used with caution, but it may be lifesaving in psychiatric or community hospitals where temporary cardiac pacemaker insertion is not performed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6842807

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  18 in total

Review 1.  Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs.

Authors:  Candace S Brown; Richard G Farmer; Judith E Soberman; Samantha F Eichner
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 2.  A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs?

Authors:  F A Fish; D M Roden
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

3.  Old drugs--new uses.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-11       Impact factor: 4.335

4.  Ventricular repolarization time indexes following anthracycline treatment.

Authors:  B Sarubbi; M Orditura; V Ducceschi; F De Vita; L Santangelo; F Ciaramella; G Catalano; A Iacono
Journal:  Heart Vessels       Date:  1997       Impact factor: 2.037

Review 5.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

6.  Near fatal case of self-poisoning with thioridazine.

Authors:  D Annane; F Girard; J E Fabre; J C Raphael; P Gajdos
Journal:  Intensive Care Med       Date:  1996-12       Impact factor: 17.440

7.  A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.

Authors:  Lili Aslostovar; Allison L Boyd; Mohammed Almakadi; Tony J Collins; Darryl P Leong; Rommel G Tirona; Richard B Kim; Jim A Julian; Anargyros Xenocostas; Brian Leber; Mark N Levine; Ronan Foley; Mickie Bhatia
Journal:  Blood Adv       Date:  2018-08-14

8.  Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.

Authors:  Dawood Darbar; John Kimbrough; Asif Jawaid; Robert McCray; Marylyn D Ritchie; Dan M Roden
Journal:  J Am Coll Cardiol       Date:  2008-02-26       Impact factor: 24.094

Review 9.  Physical assessment and differential diagnosis of the poisoned patient.

Authors:  K R Olson; P R Pentel; M T Kelley
Journal:  Med Toxicol       Date:  1987 Jan-Feb

10.  The disposition and elimination of stereoisomeric pairs of thioridazine 5-sulfoxide in the rat.

Authors:  P W Hale; S Melethil; A Poklis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Oct-Dec       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.